GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Debt-to-EBITDA

Abattis Bioceuticals (Abattis Bioceuticals) Debt-to-EBITDA : -0.47 (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abattis Bioceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $1.09 Mil. Abattis Bioceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.09 Mil. Abattis Bioceuticals's annualized EBITDA for the quarter that ended in Sep. 2019 was $-2.54 Mil. Abattis Bioceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2019 was -0.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Abattis Bioceuticals's Debt-to-EBITDA or its related term are showing as below:

ATTBF's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Abattis Bioceuticals Debt-to-EBITDA Historical Data

The historical data trend for Abattis Bioceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Debt-to-EBITDA Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 - - -0.54

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.53 -0.47

Competitive Comparison of Abattis Bioceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Debt-to-EBITDA falls into.



Abattis Bioceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abattis Bioceuticals's Debt-to-EBITDA for the fiscal year that ended in Sep. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.092 + 0.094) / -2.192
=-0.54

Abattis Bioceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.092 + 0.094) / -2.544
=-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2019) EBITDA data.


Abattis Bioceuticals  (OTCPK:ATTBF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Abattis Bioceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.